Wedbush: Reiterates the Beam Therapeutics (BEAM.US) rating and adjusted from better than market to better than market rating, with a target price of $57.00.
Zhitong FinanceApr 24 00:40
Beam Therapeutics Analyst Ratings
BenzingaApr 24 00:29
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
TipRanksApr 3 07:25
Beam Therapeutics Analyst Ratings
BenzingaMar 27 22:09
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
TipRanksMar 26 18:20
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating
MT NewswiresFeb 29 00:27
Barclays: Maintaining a wait-and-see rating for Beam Therapeutics (BEAM.US) shares, and the target price was adjusted from $26.00 to $42.00.
Zhitong FinanceFeb 29 00:10
Beam Therapeutics Analyst Ratings
BenzingaFeb 28 22:56
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
MT NewswiresFeb 28 20:49
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
TipRanksFeb 28 19:32
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
TipRanksFeb 28 19:00
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating
MT NewswiresFeb 28 02:15
JP Morgan Upgrades Beam to Overweight, Cites AATD Therapy Potential
Seeking AlphaJan 30 03:48
JP Morgan Upgrades Beam Therapeutics to Overweight, Raises Price Target to $40
BenzingaJan 29 18:43
Beam Therapeutics Analyst Ratings
BenzingaJan 29 18:42
B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target
BenzingaDec 15, 2023 21:37
Beam Therapeutics Analyst Ratings
BenzingaDec 15, 2023 21:36
Jefferies Downgrades Beam Therapeutics to Hold, Lowers Price Target to $30
BenzingaDec 8, 2023 19:56
Beam Therapeutics Analyst Ratings
BenzingaDec 8, 2023 19:55
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)
TipRanksNov 14, 2023 03:10
No Data
No Data